top of page

Bourel & Paris-Laplace advised Eckert & Ziegler on the acquisition of Tecnonuclear S.A.

Updated: Feb 7, 2022

A team led by our partners Martín Bourel and Marcelo Slonimsky, advised the German radioisotope company Eckert & Ziegler on the acquisition of 100% of the shares of the Argentine nuclear medicine company Tecnonuclear S.A ("Tecnonuclear"). The closing of the transaction took place on January 3, 2022.

Tecnonuclear is a leading manufacturer of Technetium-99 generators and a portfolio of related biomolecules. These so-called "cold kits" function as vectors

for the in-vivo delivery of Technetium-99 to more specific biological targets such as receptors and transporters. In tandem with the generators these generic tracers are commonly also referred to as SPECT diagnostics. Worldwide they represent the most widely used class of nuclear medicine products for the detection of cancer and cardio-vascular abnormalities.

Eckert & Ziegler is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Its main activities are cancer therapy, industrial radiometry and nuclear medical imaging. Eckert & Ziegler shares are listed in the TecDAX index of Deutsche Börse.

Counsel to Eckert & Ziegler: Bourel & Paris-Laplace: through a team led by Partners Martín Bourel and Marcelo Slonimsky, and associates Pablo Bascarán Rodriguez, Paula Pereyra Iraola, Matías Guarda, and Manuel Novaro Hueyo.

In-house counsel: Christine Pollard Counsel to shareholders of Tecnonuclear: Santurio, Andrada & Nöel, through a team formed by Moira Frehner and Hernán Andrada and Julio Silva.


Martin Bourel

Marcelo Slonimsky

Recent Posts

See All


bottom of page